Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation
Sponsor: University of Manitoba
Summary
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Official title: Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)
Key Details
Gender
All
Age Range
6 Years - 24 Years
Study Type
OBSERVATIONAL
Enrollment
160
Start Date
2025-03-01
Completion Date
2030-12-31
Last Updated
2025-09-08
Healthy Volunteers
No
Conditions
Interventions
Not applicable- observational study
It's an observational study. Participants are not assigned an intervention as part of the study.
Locations (2)
Shared Health Facilities
Winnipeg, Manitoba, Canada
University of Manitoba College of Pharmacy
Winnipeg, Manitoba, Canada